The #FDA has expanded pediatric indications for adalimumab-aaty (Yuflyma; Celltrion USA) and unbranded adalimumab-aaty to include the treatment of hidradenitis suppurativa in adolescent patients aged 12 years and older, and uveitis in pediatric patients aged 2 years and older.
about 2 months ago